Characterizing T-cell immunopeptidomes
Ontology highlight
ABSTRACT: Imunopeptidomes promise novel surface markers as ideal targets for immunotherapies, but their characterization by mass spectrometry (MS) remains challenging. Until recently, cell numbers exceeding 1.0xE9 were needed for reasonably deep immunopeptidome surveys of at least 1,000 HLA ligands. Such limitation in analytical sensitivity necessarily constrains the types of clinical specimens that can evaluated. To evaluate the feasibility of immunopeptidome profiling from limiting cell amounts, primary purified human regulatory (Treg) and conventional T cells (Tconv) were compared, evaluating the relative immunopeptide recovery from T cells isolated from individual healthy donors (N=5) versus pools (N=2 pools from 13 donors). Two donors’ Tconv were subsequently stimulated with CD3/CD28 and IL-2 and compared to resting Tconv. The combined T-cell immunopeptide dataset reported here contains over 13,000 unique peptides derived from over 5,000 proteins. In comparison to protein expression, T cell immunopeptidomes revealed complementary aspects of T cell biology, while pointing to HLA ligands specific for distinct T cell subsets (e.g., FOXP3, CD5 and WNK1). Taken together, these findings have implications for understanding conditions required to induce therapeutic immune responses and may open up new avenues for tuning Treg suppressive functions to treat cancer.
INSTRUMENT(S): Orbitrap Fusion Lumos, LTQ Orbitrap Elite
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): T Cell, Blood
SUBMITTER: Niclas Olsson
LAB HEAD: Joshua E Elias
PROVIDER: PXD007860 | Pride | 2018-03-08
REPOSITORIES: Pride
ACCESS DATA